Rodda B E
Circulation. 1983 Jun;67(6 Pt 2):I101-6.
The Timolol Myocardial Infarction Study was a completely randomized program of 1884 survivors of myocardial infarction comparing timolol maleate, 10 mg twice daily, with placebo for the secondary prevention of sudden death and reinfarction. In that study, timolol maleate reduced total mortality (152 placebo vs 98 timolol) and the incidence of first nonfatal reinfarctions (131 placebo vs 90 timolol). This report evaluates the effect of timolol in selected categories--age, sex, infarction site, heart size, transmural infarction, diabetes, smoking, multiple reinfarctions and pulse. These data document two important facts. First, the effects of timolol in the total sample were also seen in different subpopulations, and there were no major subgroups for which this positive effect would not be expected. Second, the consistency of the effects observed with respect to pulse, transmural infarction, age and infarct site are in contrast to some previous studies with practolol, propranolol, and alprenolol. Thus, beta blockers may not be identical with respect to reducing the mortality and morbidity associated with acute myocardial infarction.
噻吗洛尔心肌梗死研究是一项针对1884名心肌梗死幸存者的完全随机试验，比较了每日两次服用10毫克马来酸噻吗洛尔与安慰剂对猝死和再梗死的二级预防效果。在该研究中，马来酸噻吗洛尔降低了总死亡率（安慰剂组152例，噻吗洛尔组98例）以及首次非致命性再梗死的发生率（安慰剂组131例，噻吗洛尔组90例）。本报告评估了噻吗洛尔在特定分类中的效果——年龄、性别、梗死部位、心脏大小、透壁性梗死、糖尿病、吸烟、多次再梗死和脉搏。这些数据证明了两个重要事实。第一，在不同亚组中也观察到了噻吗洛尔在总样本中的效果，并且不存在预期不会出现这种积极效果的主要亚组。第二，在脉搏、透壁性梗死、年龄和梗死部位方面观察到的效果一致性与之前一些关于醋氨心安、普萘洛尔和阿普洛尔的研究形成对比。因此，在降低与急性心肌梗死相关的死亡率和发病率方面，β受体阻滞剂可能并不相同。
